Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: Jan 16, 2021
Date Accepted: Apr 19, 2021

The final, peer-reviewed published version of this preprint can be found here:

Using Computational Methods to Improve Integrated Disease Management for Asthma and Chronic Obstructive Pulmonary Disease: Protocol for a Secondary Analysis

Luo G, Stone BL, Sheng X, He S, Koebnick C, Nkoy FL

Using Computational Methods to Improve Integrated Disease Management for Asthma and Chronic Obstructive Pulmonary Disease: Protocol for a Secondary Analysis

JMIR Res Protoc 2021;10(5):e27065

DOI: 10.2196/27065

PMID: 34003134

PMCID: 8170556

Using Computational Methods to Improve Integrated Disease Management for Asthma and Chronic Obstructive Pulmonary Disease: Protocol for a Secondary Analysis

  • Gang Luo; 
  • Bryan L Stone; 
  • Xiaoming Sheng; 
  • Shan He; 
  • Corinna Koebnick; 
  • Flory L Nkoy

ABSTRACT

Background:

Asthma and chronic obstructive pulmonary disease (COPD) both put a heavy burden on healthcare. About 1/4 of asthma and COPD patients are prone to exacerbations, which can be greatly reduced by preventive care via integrated disease management that has a limited service capacity. To do this well requires a predictive model for exacerbation-proneness, but no such model exists. It would be suboptimal to build such models using the current model building approach for asthma and COPD, which has 2 gaps due to rarely factoring in temporal features showing early health changes and general directions. 1) Existing models for other asthma and COPD outcomes rarely use more advanced temporal features, such as the slope of the number of days to albuterol refill, and are inaccurate. 2) Existing models seldom show the reason a patient is deemed high-risk and potential interventions to cut the risk, making already occupied clinicians expend more time on chart review and overlook suitable interventions. Regular automatic explanation methods cannot deal with temporal data and well address this issue.

Objective:

To let more asthma and COPD patients obtain suitable and timely care to avert exacerbations, we will implement comprehensible computational methods to accurately predict exacerbation-proneness and recommend customized interventions.

Methods:

We will: a) use temporal features to accurately predict exacerbation-proneness; b) automatically find modifiable temporal risk factors for every high-risk patient; c) assess actionable warning’s impact on clinicians’ decisions of using integrated disease management to prevent exacerbation-proneness.

Results:

We have obtained most of the clinical and administrative data of asthma patients from 3 prominent American healthcare systems. We are retrieving the other clinical and administrative data, mostly of COPD patients, needed for the study. We intend to complete the study in 6 years.

Conclusions:

Our results will help make asthma and COPD care more proactive, effective, and efficient, improving outcomes and saving resources.


 Citation

Please cite as:

Luo G, Stone BL, Sheng X, He S, Koebnick C, Nkoy FL

Using Computational Methods to Improve Integrated Disease Management for Asthma and Chronic Obstructive Pulmonary Disease: Protocol for a Secondary Analysis

JMIR Res Protoc 2021;10(5):e27065

DOI: 10.2196/27065

PMID: 34003134

PMCID: 8170556

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.